Sfoglia per AUTORE
PONTECORVO S
Collezione AOU San Luigi di Orbassano

  

Items : 5

Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. in Journal of neurology, neurosurgery, and psychiatry / J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):914-920. doi: 10.1136/jnnp-2019-322480. Epub 2020 Jul
2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Spinicci G; Spitaleri D; Sessa E; Rovaris M; Righini I; Pontecorvo S; Petrucci L; Matta M; Paolicelli D; Maniscalco GT; Lus G; Lanzillo R; Guareschi A; Gasperini C; Gajofatto A; Esposito F; Danni MC; Cottone S; Centonze D; Costantino G; Castelli L; Cavalla P; Capello E; Bruno Bossio R; Brescia Morra V; Bonavita S; Bianco A; Bergamaschi R; Annunziata P; et alii...

Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2020 Oct;41(10):2905-2913. doi: 10.1007/s10072-020-04413-6. Epub 2020 Apr 25.
2020
AOU San Luigi di Orbassano

Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; et alii...

Cladribine vs other drugs in MS: Merging randomized trial with real-life data. in Neurology(R) neuroimmunology & neuroinflammation / Neurol Neuroimmunol Neuroinflamm. 2020 Aug 14;7(6):e878. doi: 10.1212/NXI.0000000000000878. Print 20
2020
ASL Cuneo 1
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Sormani MP; Visconti A; Landi D; Ippolito D; Esposito S; Russo CV; Barrilà C; Barone S; Grasso R; Pontecorvo S; Di Sapio A; Stromillo ML; Cordioli C; Rasia S; Sartori A; Clerici VT; Fenu G; Cocco E; Frau J; Barcella V; Frigeni B; La Gioia S; Pareja-Gutierrez L; Laroni A; Zarbo IR; Lavorgna L; Bonavita S; Perini P; Mataluni G; et alii...

First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. in Multiple sclerosis and related disorders / Mult Scler Relat Disord. 2020 Jul;42:102059. doi: 10.1016/j.msard.2020.102059. Epub 2020 Mar 16.
2020
ASL Cuneo 1
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Signori A; Sormani MP; Carmisciano L; Turano G; Ippolito D; Russo CV; Frigeni B; Landi D; Barrilà C; Barone S; Lavorgna L; Grasso R; Di Sapio A; Cerqua R; Pontecorvo S; Stromillo ML; Cordioli C; Signoriello E; Rasia S; Sartori A; Zarbo IR; Laroni A; Frau J; Cocco E; Torri Clerici V; La Gioia S; Gutierrez LP; Clerico M; Mataluni G; et alii...

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. in Journal of neurology / J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.
2018
AOU San Luigi di Orbassano

Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;